limited to non-steroidal anti-inflammatories (NSAIDs) and corticosteroids, treatment options now include synthetic disease modifying anti-rheumatic drugs (sDMARDs) and biologic agents. The development of national registries for inflammatory arthritis provides an opportunity to study medication usage in a large cohort of patients with axSpA. The Ankylosing Spondylitis Registry of Ireland (ASRI) is a source of epidemiological data on patients with axSpA in Ireland. The aim of this study was to examine medication exposure and outcomes.

Objectives: To characterize a large cohort of patients with axSpA in terms of medications usage, burden of disease and patient reported outcomes.

Methods: The patient population registered in the ASRI was analysed using IBM SPSS version 26. Patients were analyzed on the basis of medication exposure. The four treatment groups were classified as no treatment, NSAIDs only, biologics only, or biologics and NSAIDs. Mean age, duration of disease and delay to diagnosis was compared between groups. Burden of disease was assessed via mean BASDAI, BASFI, BASMI, HAQ and ASQoL between the four groups. Differences between groups was tested for statistical significance a one-way analysis of variance (ANOVA). A chi-squared test for independence was used to compare differences in rates of HLA-B27 positivity rates and gender. Results were deemed significant where $p < 0.05$.

Results: At present 860 patients are currently enrolled in the ASRI with 76.6% (659) males and 23.4% (201) females. Average age of patients is 45.8 years, mean disease duration of 19.4 years with 95.5% (821) of patients listed as Caucasian. Mean scores were BASDAI 4.02, BASFI 3.7, BASMI 4.02, HAQ 0.55, and ASQoL of 6.51. Treatment groups were made up of 9.9% (85) on no treatment, 22.2% (191) NSAIDs treatment only, 34.8% (299) biologics treatment only and 32.1% (276) treated with both NSAIDs and biologics. Patients only on NSAIDs were noted to be older than patients on biologics, and those on both biologics and NSAIDs ($p=0.02$). Patients on NSAIDs were older at symptom onset than those on both biologic and NSAID treatment ($p=0.02$), however the effect size is small (0.012). No significant difference was noted between groups regarding disease duration, delay to diagnosis or distribution between genders (table 1). Difference in BASDAI scores between groups was significant between all groups, with patients on both biologics and NSAIDs having the highest scores and those on no treatment with the lowest scores (4.74 vs 3.37) possibly a reflection of disease severity (table 2).

Table 1.

	ASRI	No tx	NSAIDs tx	Biologic tx	Biologic & NSAID	Sp value
Number	860	9.9% (85)	22.2% (191)	37.8% (299)	32.1% (276)	
Age	45.8	49.7	46.2	45.3	45.1	0.02
Symptom onset	26.4	27.5	28.2	26.1	25.2	0.02
Disease duration	19.4	22.2	18	19.1	19.8	0.06
Delay to dx	8	9.8	8.1	7.4	8	0.13

Table 2.

	ASRI	No tx	NSAIDs tx	Biologic tx	Biologic & NSAIDs	p value	Effect Size
BASDAI	4.02	3.37	4.21	3.4	4.74		0.06
		3.37	4.21		4.74	0.04	
		3.37			4.74	<0.01	
			4.21	3.4		<0.01	
				3.4	4.74	<0.01	

Conclusion: A large proportion of patients in the ASRI were treated with either biologics only or both biologics and NSAIDs. No treatment was the least common treatment within this cohort. Patients not on treatment tended to be older than those on any type of treatment. Overall patients on biologics alone tended to have better patient reported outcomes as compared to all other treatment groups. The development of longitudinal data for the ASRI will help to further understand the reason behind these differences.

Disclosure of Interests: Sinead Maguire Grant/research support from: ASRI is supported by funding from Pfizer, AbbVie and UCB, Phil Gallagher: None declared, Finbar Barry O'Shea Grant/research support from: ASRI is supported by funding from Pfizer, AbbVie and UCB

DOI: 10.1136/annrheumdis-2020-eular.4223

AB0705

INCIDENCE, TREND AND FACTORS ASSOCIATED WITH AMYLOIDOSIS IN PATIENTS WITH SPONDYLOARTHRITIS IN SPAIN. OBSERVATIONAL STUDY BASED ON THE REGISTRATION OF DISCHARGES OF THE GENERAL HOSPITALS OF THE NATIONAL HEALTH SYSTEM (CMBD). (TREND-ESPA STUDY)

R. Mazzucchelli¹, N. Crespi-Villarias², E. Perez-Fernandez³, R. Almodovar⁴, J. Quirós⁴, P. Zarco-Montejo⁴ on behalf of TREND-Espa. ¹Hospital Universitario

Fundación Alcorcón, Rheumatology Unit, Alcorcón. Madrid, Spain; ²Health Center Rivota, Alcorcón, Spain; ³Hospital Universitario Fundación Alcorcón, Investigation Unit, Alcorcón, Spain; ⁴Hospital Universitario Fundación Alcorcón, Rheumatology Unit, Alcorcón, Spain

Background: Amyloidosis (AA) is a complication of inflammatory diseases, such as Spondyloarthritis (Spa). It is related to active and long-lasting disease. The treatment of Spa has had a major change in recent years, which has allowed a better control of disease activity.

Objectives: Analyze the incidence, trend and factors associated with secondary AA hospitalizations in patients with Spa, in Spain.

Methods: Population study based on the analysis of a national administrative database (CMBD) of hospital admissions. **Period:** 01/01/1999 to 31/12/2015.

Study population: patients with diagnosis of Spa who were admitted to any national hospital. **Control population:** 2 groups have been used as controls: **GP:** group of the general population (without Spa diagnosis) matched of equal sex, age, year and autonomous community as the study population. **RA:** all income, in the same period, of patients diagnosed with Rheumatoid Arthritis (RA). Secondary AA admissions were identified by the presence of code 277.3. The trend was analyzed using Generalized Linear Models (MLG). The Odds Ratio (OR) of secondary amyloidosis was calculated in Spa vs GP and Spa vs AR.

Results: The database (BD) for analysis consists: **1. Study population:** 102,609 admissions with Spa diagnosis. **2. GP:** 102,609 admissions matched with the study population. **3.- RA:** 320,332 admissions. There was a total of 3,790 admissions with AA diagnosis: 782 (0.79%) at Spa, 74 (0.06%) GP and 2,924 (0.91%) RA. The main clinical-demographic characteristics patients with Spa and AA versus the rest of Spa are shown in the following table:

	Spa_ Amyloidosis	Spa_without amyloidosis	OR	IC95%	p-value
N (%)	782 (0,72)	101827 (99,28)			
Mean Age (SD)	55,9 (13,15)	58,9715 (5)	0,98	0,98-0,99	p<0,001
Mean Charlson Index (SD)	1,80 (1,34)	1,14 (1,81)	1,15	1,12-1,18	p<0,001
ALOS (SD)	12,78 (15,12)	10,57 (15,37)	1,01	1,00-1,008	p<0,001
Male n (%)	596 (75,2)	70792 (66,56)	1,52	1,29-1,79	p<0,001
Dead during admission, n (%)	82 (10,35)	3537 (3,32)	3,35	2,66-4,22	p<0,001
Areact (%)	20 (2,52)	2178 (2,04)	1,23	0,79-1,93	p=0,318
Spa_EII (%)	81 (10,22)	5238 (4,92)	2,19	1,74-2,77	p<0,001
AS (%)	538 (67,92)	67207 (63,19)	1,23	1,06-1,43	p<0,001
PAAs (%)	243 (30,68)	37673 (35,42)	0,8	0,69-0,93	p=0,005
Psoriasis (%)	24 (3,03)	2917 (2,74)	1,1	0,73-1,66	p=0,595
Uveitis (%)	12 (1,51)	542 (0,50)	3,01	1,68-5,34	p<0,001
Diabetes mellitus (%)	34 (4,29)	14822 (13,93)	0,27	0,19 - 0,39	p<0,001
Dementia (%)	3 (0,37)	626 (0,58)	0,64	0,2-2	p=0,638
HTA (%)	185 (23,35)	31395 (29,52)	0,72	0,61 - 0,85	p<0,001
Tabaquismo (%)	56 (7,07)	13283 (12,49)	0,53	0,40 - 0,69	p<0,001
Hiperlipemia (%)	99 (12,5)	17748 (16,68)	0,71	0,57-0,88	p<0,001
TVP (%)	7 (0,88)	648 (0,60)	1,45	0,68-3,07	p=0,351
Depresión (%)	23 (2,90)	5939 (5,58)	0,5	0,33-0,76	p<0,001
Tbc (%)	3 (0,37)	544 (0,51)	0,73	0,23-2,30	p=0,803

The age-adjusted rates (/100,000hab*year) of AA in Spa/GP/RA were 16.72 / 1.40 / 97.87 respectively (19.54 / 1.26 / 139.70 in men and 12.23 / 1.74 / 04.54 in women). Age-adjusted AA rates decreased in both Spa from 19.86/100,000hab*year in 1999, to 9.91 in 2015 and for RA from 131.9 in 1999 to 68.7 in 2015). While in GP increased (from 0.75 in 1999 to 2.87 in 2015). It is estimated a decrease (adjusted by age) in Spa of -4.6% per year and -5.5% in Ra, while in PG there was an increase of 10.2%. The AA OR in Spa vs GP is 10.77 (IC95%: 8,489-13,676). While the AA OR in Spa vs RA was 0.808 (95% CI: 0.747-0.875).

Conclusion: In Spain, during the period 1999 to 2015, there has been a decrease in the incidence of AA in patients with Spa and Ra. We estimate a decrease of -4.6% per year in Spa and -5.5% per year in Ra. Being male, AS or Spa_EII, and uveitis are associated with AA.

Disclosure of Interests: Ramón Mazzucchelli: None declared, Natalia Crespi-Villarias: None declared, Elia Perez-Fernandez: None declared, RAQUEL ALMODOVAR Speakers bureau: Abbvie, Celgene, Janssen, Lilly, Novartis, Pfizer., Javier Quirós: None declared, Pedro Zarco-Montejo Speakers bureau: Abbvie, MSD, Novartis, Pfizer.

DOI: 10.1136/annrheumdis-2020-eular.738

AB0706

ASSOCIATION BETWEEN SARCIDOSIS AND SPONDYLOARTHRITIS: A NEW COMORBIDITY, CHANCE OR SELECTION ERROR? (TREND-ESPA STUDY)

R. Mazzucchelli¹, N. Crespi-Villarias², R. Almodovar¹, E. Perez-Fernandez³, J. Quirós⁴, P. Zarco-Montejo⁴ on behalf of TREND-Espa. ¹Hospital Universitario Fundación Alcorcón, Rheumatology Unit, Alcorcón, Spain; ²Health Center Rivota, Alcorcón, Spain; ³Hospital Universitario Fundación Alcorcón, Investigation Unit, Alcorcón, Spain